View Financial HealthAkdital 배당 및 자사주 매입배당 기준 점검 0/6Akdital 은(는) 현재 수익률이 1.2% 인 배당금 지급 회사입니다.핵심 정보1.2%배당 수익률-0.008%자사주 매입 수익률총 주주 수익률1.2%미래 배당 수익률3.4%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Jul 14Upcoming dividend of د.م10.00 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 31 July 2025. Trailing yield: 0.7%. Lower than top quartile of Moroccan dividend payers (4.1%). Lower than average of industry peers (2.6%).Declared Dividend • May 23Dividend increased to د.م10.00Dividend of د.م10.00 is 67% higher than last year. Ex-date: 21st July 2025 Payment date: 31st July 2025 Dividend yield will be 0.7%, which is lower than the industry average of 1.7%. Sustainability & GrowthUpcoming Dividend • Jul 12Upcoming dividend of د.م6.00 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 31 July 2024. Trailing yield: 0.4%. Lower than top quartile of Moroccan dividend payers (4.4%). Lower than average of industry peers (1.8%).모든 업데이트 보기Recent updatesMajor Estimate Revision • May 20Consensus revenue estimates decrease by 23%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from د.م8.14b to د.م6.25b. EPS estimate unchanged from د.م46.13 per share at last update. Healthcare industry in Morocco expected to see average net income growth of 20% next year. Consensus price target down from د.م1,716 to د.م1,681. Share price fell 3.9% to د.م1,166 over the past week.공시 • May 18Akdital S.A, Annual General Meeting, Jun 19, 2026Akdital S.A, Annual General Meeting, Jun 19, 2026. Location: angle avenue des far et rue arrachid, casablanca 20000, casablanca MoroccoReported Earnings • May 06Full year 2025 earnings releasedFull year 2025 results: Revenue: د.م4.41b (up 49% from FY 2024). Net income: د.م443.7m (up 41% from FY 2024). Profit margin: 10% (in line with FY 2024). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Global Healthcare industry.New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (17% operating cash flow to total debt). High level of non-cash earnings (66% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).Valuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to د.م980, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 11x in the Healthcare industry in Africa. Total returns to shareholders of 245% over the past three years.Board Change • Feb 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Mohammed Benhalima was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Dec 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Mohammed Benhalima was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Dec 25Akdital S.A (CBSE:AKT) signed a memorandum of understanding to acquire Taoufik Hospitals Group for $90 million.Akdital S.A (CBSE:AKT) signed a memorandum of understanding to acquire Taoufik Hospitals Group for $90 million on December 23, 2025. A cash consideration of $90 million will be paid by Akdital S.A. As part of consideration, $90 million is paid towards common equity of Taoufik Hospitals Group. For the period ending December 31, 2024, Taoufik Hospitals Group reported total revenue of $45 million. The completion of the transaction remains subject to customary regulatory approvals.Upcoming Dividend • Jul 14Upcoming dividend of د.م10.00 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 31 July 2025. Trailing yield: 0.7%. Lower than top quartile of Moroccan dividend payers (4.1%). Lower than average of industry peers (2.6%).Declared Dividend • May 23Dividend increased to د.م10.00Dividend of د.م10.00 is 67% higher than last year. Ex-date: 21st July 2025 Payment date: 31st July 2025 Dividend yield will be 0.7%, which is lower than the industry average of 1.7%. Sustainability & Growth공시 • May 21Akdital S.A, Annual General Meeting, Jun 18, 2025Akdital S.A, Annual General Meeting, Jun 18, 2025.Price Target Changed • Apr 11Price target increased by 18% to د.م1,493Up from د.م1,267, the current price target is an average from 2 analysts. New target price is 17% above last closing price of د.م1,280. Stock is up 73% over the past year.Major Estimate Revision • Apr 11Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from د.م4.59b to د.م4.66b. EPS estimate increased from د.م32.07 to د.م35.37 per share. Net income forecast to grow 79% next year vs 39% growth forecast for Healthcare industry in Morocco. Consensus price target up from د.م1,267 to د.م1,493. Share price rose 2.4% to د.م1,280 over the past week.New Risk • Mar 27New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 12% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (12% operating cash flow to total debt). High level of non-cash earnings (91% accrual ratio).Reported Earnings • Mar 26Full year 2024 earnings releasedFull year 2024 results: Revenue: د.م2.95b (up 55% from FY 2023). Net income: د.م314.6m (up 80% from FY 2023). Profit margin: 11% (up from 9.2% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Healthcare industry in Africa.Price Target Changed • Mar 21Price target increased by 12% to د.م1,267Up from د.م1,127, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of د.م1,256. Stock is up 85% over the past year.Board Change • Feb 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Mohammed Benhalima was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Dec 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Mohammed Benhalima was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 03First half 2024 earnings releasedFirst half 2024 results: Revenue: د.م1.25b (up 51% from 1H 2023). Net income: د.م112.9m (up 69% from 1H 2023). Profit margin: 9.0% (up from 8.1% in 1H 2023). Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in Africa.New Risk • Jul 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks High level of debt (49% net debt to equity). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (12% increase in shares outstanding).Upcoming Dividend • Jul 12Upcoming dividend of د.م6.00 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 31 July 2024. Trailing yield: 0.4%. Lower than top quartile of Moroccan dividend payers (4.4%). Lower than average of industry peers (1.8%).Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 17%After last week's 17% share price gain to د.م800, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 11x in the Healthcare industry in Africa. Total returns to shareholders of 115% over the past year.New Risk • Apr 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (49% net debt to equity). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).Buy Or Sell Opportunity • Feb 13Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 41% to د.م683. The fair value is estimated to be د.م558, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 19% per annum. Earnings are also forecast to grow by 26% per annum over the same time period.Buying Opportunity • Dec 22Now 20% undervaluedOver the last 90 days, the stock is up 16%. The fair value is estimated to be د.م621, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 115% in 2 years. Earnings is forecast to grow by 138% in the next 2 years.Buying Opportunity • Nov 07Now 20% undervaluedOver the last 90 days, the stock is up 23%. The fair value is estimated to be د.م621, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 115% in 2 years. Earnings is forecast to grow by 138% in the next 2 years.New Risk • Oct 01New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 61% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to د.م472, the stock trades at a trailing P/E ratio of 68.2x. Average forward P/E is 19x in the Healthcare industry in Africa.New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, AKT 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: AKT 의 배당금 지급이 증가했지만 회사는 3 년 동안만 배당금을 지급했습니다.배당 수익률 vs 시장Akdital 배당 수익률 vs 시장AKT의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (AKT)1.2%시장 하위 25% (MA)2.2%시장 상위 25% (MA)4.6%업계 평균 (Healthcare)3.4%분석가 예측 (AKT) (최대 3년)3.4%주목할만한 배당금: AKT 의 배당금( 1.2% )은 MA 시장에서 배당금 지급자의 하위 25%( 2.18% )와 비교해 주목할 만하지 않습니다.고배당: AKT 의 배당금( 1.2% )은 MA 시장에서 배당금 지급자의 상위 25%( 4.64% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 AKT 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: AKT 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YMA 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/08 09:11종가2026/06/08 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Akdital S.A는 4명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kais KriaaAlphaMenaRim Ben Salah GharbiAlphaMenaDounia FilaliBmce Capital Bourse1명의 분석가 더 보기
Upcoming Dividend • Jul 14Upcoming dividend of د.م10.00 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 31 July 2025. Trailing yield: 0.7%. Lower than top quartile of Moroccan dividend payers (4.1%). Lower than average of industry peers (2.6%).
Declared Dividend • May 23Dividend increased to د.م10.00Dividend of د.م10.00 is 67% higher than last year. Ex-date: 21st July 2025 Payment date: 31st July 2025 Dividend yield will be 0.7%, which is lower than the industry average of 1.7%. Sustainability & Growth
Upcoming Dividend • Jul 12Upcoming dividend of د.م6.00 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 31 July 2024. Trailing yield: 0.4%. Lower than top quartile of Moroccan dividend payers (4.4%). Lower than average of industry peers (1.8%).
Major Estimate Revision • May 20Consensus revenue estimates decrease by 23%The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from د.م8.14b to د.م6.25b. EPS estimate unchanged from د.م46.13 per share at last update. Healthcare industry in Morocco expected to see average net income growth of 20% next year. Consensus price target down from د.م1,716 to د.م1,681. Share price fell 3.9% to د.م1,166 over the past week.
공시 • May 18Akdital S.A, Annual General Meeting, Jun 19, 2026Akdital S.A, Annual General Meeting, Jun 19, 2026. Location: angle avenue des far et rue arrachid, casablanca 20000, casablanca Morocco
Reported Earnings • May 06Full year 2025 earnings releasedFull year 2025 results: Revenue: د.م4.41b (up 49% from FY 2024). Net income: د.م443.7m (up 41% from FY 2024). Profit margin: 10% (in line with FY 2024). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Global Healthcare industry.
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (17% operating cash flow to total debt). High level of non-cash earnings (66% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
Valuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to د.م980, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 11x in the Healthcare industry in Africa. Total returns to shareholders of 245% over the past three years.
Board Change • Feb 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Mohammed Benhalima was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Dec 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Mohammed Benhalima was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Dec 25Akdital S.A (CBSE:AKT) signed a memorandum of understanding to acquire Taoufik Hospitals Group for $90 million.Akdital S.A (CBSE:AKT) signed a memorandum of understanding to acquire Taoufik Hospitals Group for $90 million on December 23, 2025. A cash consideration of $90 million will be paid by Akdital S.A. As part of consideration, $90 million is paid towards common equity of Taoufik Hospitals Group. For the period ending December 31, 2024, Taoufik Hospitals Group reported total revenue of $45 million. The completion of the transaction remains subject to customary regulatory approvals.
Upcoming Dividend • Jul 14Upcoming dividend of د.م10.00 per shareEligible shareholders must have bought the stock before 21 July 2025. Payment date: 31 July 2025. Trailing yield: 0.7%. Lower than top quartile of Moroccan dividend payers (4.1%). Lower than average of industry peers (2.6%).
Declared Dividend • May 23Dividend increased to د.م10.00Dividend of د.م10.00 is 67% higher than last year. Ex-date: 21st July 2025 Payment date: 31st July 2025 Dividend yield will be 0.7%, which is lower than the industry average of 1.7%. Sustainability & Growth
공시 • May 21Akdital S.A, Annual General Meeting, Jun 18, 2025Akdital S.A, Annual General Meeting, Jun 18, 2025.
Price Target Changed • Apr 11Price target increased by 18% to د.م1,493Up from د.م1,267, the current price target is an average from 2 analysts. New target price is 17% above last closing price of د.م1,280. Stock is up 73% over the past year.
Major Estimate Revision • Apr 11Consensus EPS estimates increase by 10%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has improved. 2025 revenue forecast increased from د.م4.59b to د.م4.66b. EPS estimate increased from د.م32.07 to د.م35.37 per share. Net income forecast to grow 79% next year vs 39% growth forecast for Healthcare industry in Morocco. Consensus price target up from د.م1,267 to د.م1,493. Share price rose 2.4% to د.م1,280 over the past week.
New Risk • Mar 27New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 12% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (12% operating cash flow to total debt). High level of non-cash earnings (91% accrual ratio).
Reported Earnings • Mar 26Full year 2024 earnings releasedFull year 2024 results: Revenue: د.م2.95b (up 55% from FY 2023). Net income: د.م314.6m (up 80% from FY 2023). Profit margin: 11% (up from 9.2% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Healthcare industry in Africa.
Price Target Changed • Mar 21Price target increased by 12% to د.م1,267Up from د.م1,127, the current price target is an average from 2 analysts. New target price is approximately in line with last closing price of د.م1,256. Stock is up 85% over the past year.
Board Change • Feb 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Mohammed Benhalima was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Dec 25Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Mohammed Benhalima was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 03First half 2024 earnings releasedFirst half 2024 results: Revenue: د.م1.25b (up 51% from 1H 2023). Net income: د.م112.9m (up 69% from 1H 2023). Profit margin: 9.0% (up from 8.1% in 1H 2023). Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare industry in Africa.
New Risk • Jul 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 12% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks High level of debt (49% net debt to equity). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (12% increase in shares outstanding).
Upcoming Dividend • Jul 12Upcoming dividend of د.م6.00 per shareEligible shareholders must have bought the stock before 19 July 2024. Payment date: 31 July 2024. Trailing yield: 0.4%. Lower than top quartile of Moroccan dividend payers (4.4%). Lower than average of industry peers (1.8%).
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improves as stock rises 17%After last week's 17% share price gain to د.م800, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 11x in the Healthcare industry in Africa. Total returns to shareholders of 115% over the past year.
New Risk • Apr 12New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (49% net debt to equity). Latest financial reports are more than 6 months old (reported June 2023 fiscal period end).
Buy Or Sell Opportunity • Feb 13Now 22% overvalued after recent price riseOver the last 90 days, the stock has risen 41% to د.م683. The fair value is estimated to be د.م558, however this is not to be taken as a sell recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 19% per annum. Earnings are also forecast to grow by 26% per annum over the same time period.
Buying Opportunity • Dec 22Now 20% undervaluedOver the last 90 days, the stock is up 16%. The fair value is estimated to be د.م621, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 115% in 2 years. Earnings is forecast to grow by 138% in the next 2 years.
Buying Opportunity • Nov 07Now 20% undervaluedOver the last 90 days, the stock is up 23%. The fair value is estimated to be د.م621, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 115% in 2 years. Earnings is forecast to grow by 138% in the next 2 years.
New Risk • Oct 01New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 61% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improves as stock rises 17%After last week's 17% share price gain to د.م472, the stock trades at a trailing P/E ratio of 68.2x. Average forward P/E is 19x in the Healthcare industry in Africa.
New Risk • Sep 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (37% accrual ratio). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).